Balkrishna Industries Ltd Q4 FY2025 Concall Summary

Key Takeaways

• A 5-year transformation unveiled: Management set a ~INR23,000 cr revenue target by 2030, built on three new growth engines beyond the core OHT franchise: rubber tracks, carbon black third-party sales, and entry into India's PCR and TBR replacement markets.
• Q4 PAT down 25% YoY to INR362 cr, driven by a INR58 cr M2M loss and higher finance costs, masking a solid 5% revenue rise and full-year volume growth of 8%.
• Margins are expected to dip before they recover: Management guided to a 23-25% steady-state EBITDA margin once new projects mature, acknowledging a period of sub-scale dilution in FY28-FY29.
• A INR3,500 cr capex cycle is front-loaded into FY26 and FY27, funded by internal accruals, with benefits only materializing from FY28 onwards.
• What to watch next quarter: Any quantification of the pilot capacities for PCR and TBR, the hedge rate for FY26, and the actual impact of potential U.S. tariff hikes from June 1.

The 2030 Strategic Roadmap

• Revenue ambition: Target of ~INR23,000 cr by FY30, a near-doubling from FY25's INR10,615 cr, to be achieved via three levers.
• OHT remains the anchor: Expected to contribute 70% of enhanced revenue, with a conservative global market share target of 8% and an aspirational goal of 10%.
• Carbon black third-party sales: Aiming for 10% of FY30 revenue, supported by a board-approved capacity expansion from 200,000 MT to 360,000 MT per annum, plus a 24 MW cogeneration plant at Bhuj, expected by early '26.
• New tire verticals in India: Targeting ~20% of overall sales by 2030, equating to a ~5% domestic market share, through a modular entry into premium PCR and TBR segments focused initially on the replacement market.
• Pilot timelines: TBR pilot to launch in Q4 FY26, leveraging existing mining TBR capacity; PCR pilot to follow in Q3 FY27, with capacity planning still being worked on.
• No technological tie-ups needed: Management expressed full confidence in its in-house R&D capability to develop the new product lines without external partnerships.

Poddar: "At BKT, we are focusing not on the near term, but for the next 25 years of business growth."

Capex & Capacity Build-Out

• Total outlay: INR3,500 cr over the next 3 years, funded mainly through internal accruals, with peak combined annual spend between INR1,500 cr and INR1,800 cr.
• Front-loaded phasing: Heavy spends concentrated in FY26 (INR1,000-1,500 cr) and FY27, with a smaller amount in FY28; management declined to provide a segment-wise breakup as the budget was just approved.
• OHT capacity: An already-approved 35,000 MT expansion is underway, taking total capacity to 425,000-430,000 MT per annum, with minor future debottlenecking via maintenance capex of INR500-700 cr.
• Rubber tracks facility: A dedicated manufacturing plant is approved, with production expected to commence in H2 FY26, expanding the pilot into agricultural, construction, and industrial track applications.
• Benefit timeline: Management explicitly stated that the financial benefits of this capex cycle will be reaped from FY28 to FY30, implying a multi-year gestation period.

Poddar: "It will be '26 and '27 and then you will start reaping the benefits of it in '28 to '30."

Margin & Return Profile Outlook

• Steady-state margin: Management expects blended EBITDA margins to settle in the 23% to 25% range once all new projects achieve full commercialization and scale.
• Interim dilution expected: Margins are projected to be marginally lower in FY28 and FY29 while the new businesses are sub-scale, before recovering to the steady-state level.
• Q4 margin dip explained: The 24.8% Q4 EBITDA margin reflected peaking raw material prices; a 1-2% decline was characterized as in line with expectations, with a ~1% benefit anticipated next quarter as raw material costs ease slightly.
• ROCE confidence: Management does not anticipate a significant decline in overall ROCE once the full potential of the new ventures is achieved, though internal targets for new business ROCE were not disclosed.
• Premium niche strategy: Margin resilience in competitive PCR/TBR segments is predicated on focusing on premium niches within those sectors, not generic levels, which management believes will prevent significant dilution.

Poddar: "despite entering competitive segments, our overall -- at peak, once we achieve full expansion and revenue, our EBITDA margins may not be diluted that much because we are going to focus on premium niches within these sectors. So we are not going to be catering at generic levels."

Core OHT Business & Market Position

• Market share gains: The company has steadily grown its global OHT market share from 2% to approximately 6% over the last few years, with a stated conservative target of 8% by 2030.
• FY25 volume growth: Full-year volumes grew 8% YoY to 315,273 MT, exceeding expectations, despite a flat Q4 at 82,062 MT.
• Realization improvement: A 3% QoQ improvement in realizations was driven by product mix and hedge rates, not by price hikes in the U.S. market.
• U.S. tariff uncertainty: The impact of trade wars is being managed via a sharing arrangement, but management deemed it too early to comment on the potential impact of further tariff hikes expected from June 1.
• No FY26 volume guidance: Citing a volatile global scenario with trade wars and geopolitical conflicts, management declined to provide any volume guidance for the core OHT business in the coming year.

Poddar: "we are currently at 6% and we are seeing the business growing to about 8%. However, as I mentioned, our global vision yet remains our ambition remains to be 10%. Please note that we are under a slow-moving economy. There are wars happening, there are trade wars happening. Uncertain times are there. So that is why we are looking at it very conservatively."

New Business Details & Open Questions

• Carbon black specialty: The business started only in September last year; trials are ongoing and will take time to progress, with some utilization expected by '27, though the timeline remains vague.
• PCR and TBR specifics withheld: Management declined to disclose target sub-segments within PCR (e.g., rim size) or TBR, the capacities of the pilot plants, or the specific financial and ROCE parameters used to greenlight the entry, stating it was too early or strategically sensitive.
• Raw material strategy undefined: With 30% of future business coming from outside OHT, management admitted its strategy to cope with increased raw material volatility from new businesses is "a work in progress" and too early to define.
• Brand spend maintained: Absolute brand investment levels will be maintained, meaning the percentage spend will naturally decline as enhanced turnover is reached, with cumulative benefits expected towards the end of the 5-year journey.

Guidance & Commitments

Key Metrics